Skip to main content
Erschienen in: World Journal of Urology 4/2018

25.02.2017 | Letter to the Editor

No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer

verfasst von: Peter B. Østergren, Tobias Wirenfeldt Klausen, Mikkel Fode

Erschienen in: World Journal of Urology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M, Faria EF (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628CrossRefPubMed Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M, Faria EF (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628CrossRefPubMed
2.
Zurück zum Zitat Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo 49(9):521–525PubMed Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo 49(9):521–525PubMed
3.
Zurück zum Zitat Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi:10.1016/j.juro.2016.12.003 (Epub ahead of print) PubMed Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi:10.​1016/​j.​juro.​2016.​12.​003 (Epub ahead of print) PubMed
4.
Zurück zum Zitat Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46CrossRefPubMedPubMedCentral Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van HM (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251CrossRefPubMed O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van HM (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251CrossRefPubMed
Metadaten
Titel
No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer
verfasst von
Peter B. Østergren
Tobias Wirenfeldt Klausen
Mikkel Fode
Publikationsdatum
25.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-017-2012-x

Weitere Artikel der Ausgabe 4/2018

World Journal of Urology 4/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.